New metabolic warnings added to olanzapine product labels
Labels for Eli Lilly's olanzapine (Zyprexa) and olanzapine/fluoxetine (Symbyax) have been updated to include stronger warnings regarding the potential for drug-associated metabolic changes. The changes include new warnings for weight gain, hyperlipidemia, and hyperglycemia and additional language stating that there is a greater association between olanzapine and increases in glucose levels than with some other atypical antipsychotics. Lilly said it will provide additional data and analysis to the FDA as they become available. The added warnings can be accessed online at www.symbyax.com.